NASDAQ : SGP
SpyGlass Pharma, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 32.51 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.09B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Selling, General & Admin | 26.82M | 12.27M | 7.08M |
| Research & Development | 35.28M | 29.18M | 19.98M |
| Operating Expenses | 62.10M | 41.45M | 27.06M |
| Operating Income | -62.10M | -41.45M | -27.06M |
| Interest & Investment Income | 6.05M | 3.11M | 1.32M |
| Other Non Operating Income (Expenses) | -1.53M | -3.42M | |
| Pretax Income | -56.05M | -39.87M | -29.16M |
| Net Income | -56.05M | -39.87M | -29.16M |
| Net Income to Common | -56.05M | -39.87M | -29.16M |
| Shares Outstanding (Basic) | 14.45M | 2.22M | 1.79M |
| Shares Outstanding (Diluted) | 14.45M | 2.22M | 1.79M |
| EPS (Basic) | -3.88 | -17.98 | -16.31 |
| EPS (Diluted) | -3.88 | -17.98 | -16.31 |
| Free Cash Flow | -49.74M | -33.49M | -24.02M |
| Free Cash Flow Per Share | -3.44 | -15.11 | -13.43 |
| EBITDA | -61.09M | -40.84M | -26.79M |
| D&A For EBITDA | 1.01M | 612.00K | 271.00K |
| EBIT | -62.10M | -41.45M | -27.06M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 223.14M | 96.36M | 16.27M |
| Short-Term Investments | 11.04M | 11.08M | |
| Cash & Short-Term Investments | 234.19M | 107.44M | 16.27M |
| Other Receivables | 678.00K | 431.00K | 423.00K |
| Receivables | 678.00K | 431.00K | 423.00K |
| Prepaid Expenses | 1.60M | 901.00K | 715.00K |
| Total Current Assets | 236.46M | 108.77M | 17.41M |
| Property, Plant & Equipment | 6.21M | 3.89M | 5.46M |
| Long-Term Deferred Charges | 2.71M | ||
| Other Long-Term Assets | 759.00K | 492.00K | 453.00K |
| Total Assets | 243.43M | 115.87M | 23.32M |
| Accounts Payable | 4.16M | 2.70M | 1.98M |
| Accrued Expenses | 1.72M | 2.18M | 1.28M |
| Current Portion of Leases | 442.00K | ||
| Other Current Liabilities | 3.56M | 3.71M | 4.09M |
| Total Current Liabilities | 9.44M | 8.58M | 7.79M |
| Long-Term Leases | 1.63M | 1.58M | 3.46M |
| Total Liabilities | 11.07M | 10.17M | 11.25M |
| Additional Paid-In Capital | 370.78M | 5.89M | 4.39M |
| Retained Earnings | -138.41M | -104.73M | -64.86M |
| Total Common Equity | 232.36M | -98.84M | -60.47M |
| Shareholders' Equity | 232.36M | 105.70M | 12.07M |
| Total Liabilities & Equity | 243.43M | 115.87M | 23.32M |
| Total Debt | 1.63M | 1.58M | 3.90M |
| Net Cash (Debt) | 232.55M | 105.85M | 12.37M |
| Net Cash Per Share | 16.09 | 47.74 | 6.92 |
| Filing Date Shares Outstanding | 33.45M | 33.43M | 1.84M |
| Total Common Shares Outstanding | 33.45M | 2.20M | 1.84M |
| Working Capital | 227.02M | 100.18M | 9.62M |
| Book Value Per Share | 6.95 | -44.85 | -32.89 |
| Tangible Book Value | 232.36M | -98.84M | -60.47M |
| Tangible Book Value Per Share | 6.95 | -44.85 | -32.89 |
| Machinery | 2.89M | 2.30M | 1.99M |
| Construction In Progress | 2.98M | 430.00K | |
| Leasehold Improvements | 584.00K | 622.00K | 622.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -56.05M | -39.87M | -29.16M |
| Depreciation & Amortization | 1.01M | 612.00K | 271.00K |
| Loss (Gain) From Sale of Assets | 1.00K | 5.00K | |
| Stock-Based Compensation | 5.61M | 2.79M | 1.49M |
| Other Operating Activities | -257.00K | 1.32M | 4.04M |
| Change in Accounts Receivable | -132.00K | -8.00K | -300.00K |
| Change in Accounts Payable | 1.45M | 549.00K | 1.34M |
| Change in Other Net Operating Assets | 1.80M | 1.91M | 299.00K |
| Operating Cash Flow | -46.56M | -32.70M | -22.03M |
| Capital Expenditures | -3.18M | -789.00K | -1.99M |
| Investment in Securities | -11.00M | -11.01M | 24.25M |
| Investing Cash Flow | -14.18M | -11.79M | 22.26M |
| Issuance of Common Stock | 145.00K | 170.00K | 185.00K |
| Repurchase of Common Stock | -1.45M | ||
| Other Financing Activities | -3.93M | -1.47M | |
| Financing Cash Flow | 156.64M | 124.58M | 185.00K |
| Net Cash Flow | 95.91M | 80.09M | 419.00K |
| Free Cash Flow | -49.74M | -33.49M | -24.02M |
| Free Cash Flow Per Share | -3.44 | -15.11 | -13.43 |
| Levered Free Cash Flow | -22.24M | ||
| Unlevered Free Cash Flow | -22.24M | ||
| Cash Income Tax Paid | 1.00K | 18.00K | |
| Change in Working Capital | 3.12M | 2.45M | 1.34M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 1.11B | ||
| Enterprise Value | 881.26M | ||
| Debt / Equity Ratio | 0.01 | 0.01 | 0.32 |
| Net Debt / Equity Ratio | -1.00 | -1.00 | -1.02 |
| Net Debt / EBITDA Ratio | 3.81 | 2.59 | 0.46 |
| Net Debt / FCF Ratio | 4.67 | 3.16 | 0.52 |
| Quick Ratio | 24.89 | 12.57 | 2.14 |
| Current Ratio | 25.06 | 12.67 | 2.23 |
| Return on Equity (ROE) | -67.70% | ||
| Return on Assets (ROA) | -37.23% | ||
| Return on Capital Employed (ROCE) | -26.50% | -38.60% | -174.30% |
| Buyback Yield / Dilution | -708.11% | -23.98% |